Seagen Names Former Novartis Oncology Chief David Epstein as CEO

Seagen Inc., the cancer drugmaker whose discussions regarding a sale to Merck & Co. stalled in August, named former Novartis AG oncology chief David Epstein to take over as chief executive officer.

Epstein, who more recently served as an executive partner with Flagship Pioneering, will also take a seat on the company’s board. Roger Dansey, who served as interim CEO since May, will become president of research and development while resuming his former role of chief medical officer, Seattle based Seagen said Thursday in a statement.

Seagen is a leader in developing treatments aimed fighting cancer ...